A Retrospective Multi-centre Non-interventional Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 27 Sep 2021 Status changed from recruiting to completed.
- 03 May 2021 Status changed from not yet recruiting to recruiting.
- 20 Apr 2021 Planned initiation date changed from 28 Feb 2021 to 3 May 2021.